NewsBenzingaMerck und Moderna berichten Phase-3-Ergebnisse der Melanom-Studie für personalisierte mRNA-Krebstherapie; Intismeran plus KEYTRUDA senkt das Risiko für ein Wiederauftreten des Melanoms oder den Tod um 42 % Merck und Moderna berichten Phase-3-Ergebnisse der Melanom-Studie für personalisierte mRNA-Krebstherapie; Intismeran plus KEYTRUDA senkt das Risiko für ein Wiederauftreten des Melanoms oder den Tod um 42 % Benzinga 2026.10.22 19:05 (GMT+0) Open on Benzinga Other news Base: Mastercard adopts agentic payments using x402 and USDC, with settlement on Base Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis - Slideshow (NYSE:NVS) 2026-10-23 US IRS Plans to Roll Out Reformed Voluntary Disclosure Program by End of November, With No Separate Procedure for Crypto Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript $1000 Invested In Mastercard 10 Years Ago Would Be Worth This Much Today Here's How Much $1000 Invested In Williams Companies 5 Years Ago Would Be Worth Today
Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis - Slideshow (NYSE:NVS) 2026-10-23
US IRS Plans to Roll Out Reformed Voluntary Disclosure Program by End of November, With No Separate Procedure for Crypto
Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript
